Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China

References

• Adamec C. (1964). [Example of the use of the nonparametric test. Test X2 for comparison of two independent examples]. Ceskoslovenske Zdravotnictvi 12:613–19
   PubMedGoogle Scholar
• Allabi AC, Gala JL, Desager JP, et al. (2003). Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56:653–7
   PubMed Web of Science ®Google Scholar
• Arvanitidis K, Ragia G, Iordanidou M, et al. (2007). Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419–26
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–5
   PubMed Web of Science ®Google Scholar
• Blaisdell J, Mohrenweiser H, Jackson J, et al. (2002). Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenet Genomics 12:703–11
   Web of Science ®Google Scholar
• Bravo-Villalta HV, Yamamoto K, Nakamura K, et al. (2005). Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol 61:179–84
   PubMed Web of Science ®Google Scholar
• Chang M, Dahl M-L, Tybring G, et al. (1995). Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenet Genomics 5:358–63
   Web of Science ®Google Scholar
• Chen L, Qin S, Xie J, et al. (2008). Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics 2008;9:691–702
   Google Scholar
• de Morais SM, Goldstein JA, Xie HG, et al. (1995). Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404–11
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, Flockhart DA. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913–58
   PubMed Web of Science ®Google Scholar
• Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. (2003). Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59:303–12
   PubMed Web of Science ®Google Scholar
• Goddard KA, Hopkins PJ, Hall JM, Witte JS. (2000). Linkage disequilibrium and allele-frequency distributions for 114 single-nucleotide polymorphisms in five populations. Am J Hum Genet 66:216–34
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Ishizaki T, Chiba K, et al. (1997). Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59–64
   PubMedGoogle Scholar
• Griese EU, Ilett KF, Kitteringham NR, et al. (2001). Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia. Pharmacogenet Genomics 11:69–76
   Web of Science ®Google Scholar
• He N, Yan FX, Huang SL, et al. (2002). CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol 58:15–18
   PubMed Web of Science ®Google Scholar
• Herrlin K, Massele AY, Jande M, et al. (1998). Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin Pharmacol Ther 64:391–401
   PubMed Web of Science ®Google Scholar
• Hu LM, Dai DP, Hu GX, et al. (2012). Genetic polymorphisms and novel allelic variants of CYP2C19 in the Chinese Han population. Pharmacogenomics 13:1571–81
   PubMed Web of Science ®Google Scholar
• Kobori L, Kohalmy K, Porrogi P, et al. (2008). Drug-induced liver graft toxicity caused by cytochrome P450 poor metabolism. Br J Clin Pharmacol 65:428–36
   PubMed Web of Science ®Google Scholar
• Masimirembwa C, Bertilsson L, Johansson I, et al. (1995). Phenotyping and genotyping of S‐mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656–61
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. (2002). Accounting for human polymorphisms predicted to affect protein function. Genome Res 12:436–46
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. (2003). SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res, 31:3812–14
   PubMed Web of Science ®Google Scholar
• Ng PC, Henikoff S. (2006). Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 7:61–80
   PubMed Web of Science ®Google Scholar
• Nowak MP, Sellers EM, Tyndale RF. (1998). Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clin Pharmacol Ther 64:378–83
   PubMed Web of Science ®Google Scholar
• Oinonen T, Lindros K. (1998). Zonation of hepatic cytochrome P-450 expression and regulation. Biochem J 329:17–35
   PubMed Web of Science ®Google Scholar
• Ozawa S, Soyama A, Saeki M, et al. (2004). Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacokinet 19:83–95
   PubMedGoogle Scholar
• Persson I, Aklillu E, Rodrigues F, et al. (1996). S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenet Genomics 6:521–6
   Web of Science ®Google Scholar
• Ragia G, Arvanitidis KI, Tavridou A, Manolopoulos VG. (2009). Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics 10:43–9
   PubMed Web of Science ®Google Scholar
• Ramensky V, Bork P, Sunyaev S. (2002). Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894–900
   PubMed Web of Science ®Google Scholar
• Scordo MG, Caputi AP, D’Arrigo C, et al. (2004). Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195–200
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, et al. (2009). Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849–57
   PubMed Web of Science ®Google Scholar
• Tamminga WJ, Wemer J, Oosterhuis B, et al. (2001). The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 57:717–22
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Mahatthanatrakul W, Niwatananun K, et al. (2006). CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab Pharmacokinet 21:286–90
   PubMed Web of Science ®Google Scholar
• Xu S, Huang W, Qian J, Jin L. (2008). Analysis of genomic admixture in Uyghur and its implication in mapping strategy. Am J Hum Genet 82:883–94
   PubMed Web of Science ®Google Scholar
• Yamada S, Onda M, Kato S, et al. (2001). Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J Gastroenterol 36:669–72
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
   PubMed Web of Science ®Google Scholar
• Zuo J, Xia D, Jia L, Guo T. (2012a). Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. Pharmazie 67:639–44
   PubMed Web of Science ®Google Scholar
• Zuo LJ, Guo T, Xia DY, Jia LH. (2012b). Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet TestMol Biomarkers 16:102–8
   PubMed Web of Science ®Google Scholar